Cargando…

Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy

INTRODUCTION: Switching to a rilpivirine, tenofovir and emtricitabine (RTE) single-tablet regimen (STR) has been evaluated in a limited number of virologically suppressed patients. The aim of this study was to describe clinical outcomes in HIV-positive patients switched from a suppressive antiretrov...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gianotti, Nicola, Poli, Andrea, Nozza, Silvia, Spagnuolo, Vincenzo, Tambussi, Giuseppe, Bossolasco, Simona, Cinque, Paola, Maillard, Myriam, Cernuschi, Massimo, Galli, Laura, Lazzarin, Adriano, Castagna, Antonella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2015
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522018/ https://www.ncbi.nlm.nih.gov/pubmed/26232000 http://dx.doi.org/10.7448/IAS.18.1.20037

Ejemplares similares

Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression
por: Carbone, Alessia, et al.
Publicado: (2014)

Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice
por: Ranzenigo, Martina, et al.
Publicado: (2022)

Predictors of lack of serological response to syphilis treatment in HIV-infected subjects
por: Spagnuolo, Vincenzo, et al.
Publicado: (2014)

Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV
por: Spagnuolo, Vincenzo, et al.
Publicado: (2018)

Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load
por: Galizzi, Nadia, et al.
Publicado: (2018)

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2019)

Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort
por: Pinnetti, Carmela, et al.
Publicado: (2014)

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia
por: Taramasso, Lucia, et al.
Publicado: (2019)

537 STaR: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF has Similar Efficacy and is Well-Tolerated Compared to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Females at Week 96
por: Creticos, Catherine, et al.
Publicado: (2014)

Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir
por: Wainberg, Mark A
Publicado: (2013)

Simultaneous Spectrophotometric Method for Determination of Emtricitabine and Tenofovir Disoproxil Fumarate in Three-Component Tablet Formulation Containing Rilpivirine Hydrochloride
por: Venkatesan, S., et al.
Publicado: (2014)

Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection
por: Bernardini, Claudia, et al.
Publicado: (2013)

Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir
por: Gianotti, Nicola, et al.
Publicado: (2016)

A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans
por: Collins, Sean E., et al.
Publicado: (2016)

Stability-Indicating HPLC Method for the Simultaneous Determination of HIV Tablet Containing Emtricitabine, Tenofovir Disoproxil Fumarate, and Rilpivirine Hydrochloride in Pharmaceutical Dosage Forms
por: Venkatesan, S., et al.
Publicado: (2014)

Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males
por: Rovelli, Cristina, et al.
Publicado: (2017)

Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide
por: Custodio, Joseph M., et al.
Publicado: (2017)

Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study
por: Neukam, Karin, et al.
Publicado: (2016)

Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial
por: Brunetta, Jason, et al.
Publicado: (2015)

HPTLC Method for the Simultaneous Estimation of Emtricitabine and Tenofovir in Tablet Dosage Form
por: Joshi, Maithilee, et al.
Publicado: (2009)

Viral Blips Were Infrequent in HIV-1-Infected Virologically-Suppressed Adults Treated with Tenofovir Alafenamide or Tenofovir DF Rilpivirine-Containing Regimens
por: Wohl, David A, et al.
Publicado: (2017)

Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2014)

Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients: A multicenter study
por: Falcon-Neyra, Lola, et al.
Publicado: (2016)

Review of tenofovir-emtricitabine
por: Masho, Saba Woldemichael, et al.
Publicado: (2007)

Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

High plasma levels of parathyroid hormone (PTH) are associated with an increased cardiovascular risk among HIV-infected subjects
por: Spagnuolo, V, et al.
Publicado: (2010)

Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US
por: Juday, Timothy, et al.
Publicado: (2013)

Spatial Distribution Profiles of Emtricitabine, Tenofovir, Efavirenz, and Rilpivirine in Murine Tissues Following In Vivo Dosing Correlate with Their Safety Profiles in Humans
por: Seneviratne, Herana Kamal, et al.
Publicado: (2020)

Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients
por: Engell, Christian A., et al.
Publicado: (2011)

Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus
por: Sax, Paul E, et al.
Publicado: (2020)

538 A Retrospective Study to Evaluate the Safety of Switching Antiretroviral Therapy (ART) to Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine (RPV/TDF/FTC) STR in Virologically Suppressed HIV-Infected Patients
por: Monczor, Ana, et al.
Publicado: (2014)

Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial
por: Wiriyatanakorn, Sirichai, et al.
Publicado: (2019)

Evaluation of Rapidly Disintegrating Vaginal Tablets of Tenofovir, Emtricitabine and Their Combination for HIV-1 Prevention
por: Clark, Meredith R., et al.
Publicado: (2014)

New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir
por: Patel, Nimish, et al.
Publicado: (2012)

Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1
Publicado: (2019)

HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens
por: Huhn, Gregory D., et al.
Publicado: (2020)

Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
por: Sax, Paul E., et al.
Publicado: (2018)

Achieving virological control in pan-resistant HIV-1 infection: A case series
por: Canetti, Diana, et al.
Publicado: (2022)

Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up
por: Charpentier, Charlotte, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_846dl442jvin097gdsek8vfdlt